Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...

Backed Nutritional Solution Targeting Respiratory and Liver Health Through Natural Detox PathwaysSheridan, April 05, 2025 ...

Echinacea is a well-known immune booster often used to prevent and treat respiratory infections. Its ability to enhance the immune response can help the body fight off pathogens contributing to ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

The trial evaluated Dupixent added to background maximal standard-of-care inhaled therapy (with nearly ... NOTUS Phase 3 trial were published in The New England Journal of Medicine. In addition to ...

The evidence that glucose-lowering medications can improve ... told Medscape Medical News. This follows a Danish clinical trial in patients with obesity and COPD that found that 40 weeks of ...

In 2019, COPD was responsible for 3.3 million ... “This document includes new information about the medications discussed in this session, but there are additional points that merit further ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...